{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:58:19Z","timestamp":1791849499073,"version":"4.3.4"},"reference-count":36,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T00:00:00Z","timestamp":1254182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Alfacalcidol (1\u03b1-hydroxyvitamin D3) has been widely used since 1981 as a prodrug for calcitriol (1\u03b1,25-dihydroxyvitamin D3) in the treatment of hypocalcemia, chronic renal failure, hypoparathyroidism and osteoporosis. More recently, doxercalciferol (1\u03b1-hydroxyvitamin D2) has been used since 1999 as a prodrug for 1\u03b1,25-dihydroxyvitamin D2 for the treatment of secondary hyperparathyroidism. Currently, six forms of vitamin D are known. They range from vitamin D2 to vitamin D7 and are distinguished by their differing side chains. Only vitamin D2 and vitamin D3 have been found to be biologically active based on the elucidation of activation pathways. Alfacalcidol and osteoporosis\/doxercalciferol and secondary hyperparathyroidism are discussed, with a new look at old compounds including their practical syntheses.<\/jats:p>","DOI":"10.3390\/molecules14103869","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T10:29:09Z","timestamp":1254220149000},"page":"3869-3880","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["A New Look at the Most Successful Prodrugs for Active Vitamin D (D Hormone): Alfacalcidol and Doxercalciferol"],"prefix":"10.3390","volume":"14","author":[{"given":"Noboru","family":"Kubodera","sequence":"first","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd., 2-1-1, Nihonbashi-Muromachi, Chuo-ku, Tokyo 103-8324, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2009,9,29]]},"reference":[{"key":"ref_1","unstructured":"Feldman, D., Glorieux, F.H., and Pike, J.W. (1997). Vitamin D, Academic Press."},{"key":"ref_2","unstructured":"Feldman, D., Pike, J.W., and Glorieux, F.H. (2005). Vitamin D, Elsevier Academic Press. [2nd ed.]."},{"key":"ref_3","unstructured":"Feldman, D., Pike, J.W., and Glorieux, F.H. (2005). Vitamin D, Elsevier Academic Press. [2nd ed.]."},{"key":"ref_4","unstructured":"Feldman, D., Pike, J.W., and Glorieux, F.H. (2005). Vitamin D, Elsevier Academic Press. [2nd ed.]."},{"key":"ref_5","unstructured":"Feldman, D., Pike, J.W., and Glorieux, F.H. (2005). Vitamin D, Elsevier Academic Press. [2nd ed.]."},{"key":"ref_6","first-page":"87","article-title":"1\u03b1-Hydroxycholecalciferol prevents osteoporosis induced by ovariectomy in the rats","volume":"68","author":"Higuchi","year":"1994","journal-title":"Vitamins"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s007740200008","article-title":"Active vitamin D and its analogs as drugs for the treatment of osteoporosis: Advantages and problems","volume":"20","author":"Nishii","year":"2002","journal-title":"J. Bone Miner. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s002239900704","article-title":"The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis","volume":"65","author":"Shiraishi","year":"1999","journal-title":"Calcif. Tissue Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S8756-3282(02)00682-8","article-title":"ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis","volume":"30","author":"Uchiyama","year":"2002","journal-title":"Bone"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00001433-199910000-00003","article-title":"The effect of vitamin D bon Osteoblasts and Osteoclasts","volume":"10","author":"Ikeda","year":"1999","journal-title":"Curr Opin Orthop"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/0006-291X(89)91140-6","article-title":"Regulatory activities of 2\u03b2-(3-hydroxypropoxy)1\u03b1,25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolism","volume":"163","author":"Okano","year":"1989","journal-title":"Biochem. Biophy. Res. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1210\/jc.2004-2552","article-title":"A new vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: A randomized, double-blind, placebo-controlled clinical trial","volume":"90","author":"Matsumoto","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/1573407210602030301","article-title":"Search for and development of active vitamin D3 analogs","volume":"2","author":"Kubodera","year":"2006","journal-title":"Curr. Bioactive Compds."},{"key":"ref_14","unstructured":"Marcus, R., Feldman, D., and Kelsey, J. (1996). Osteoporosis, Academic Press."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0039-128X(00)00227-0","article-title":"History of the development of new vitamin D analogs: Studies on 22-oxacalcitriol (OCT) and 2\u03b2-(3-hydroxypropoxy)calcitriol (ED-71)","volume":"66","author":"Nishii","year":"2001","journal-title":"Steroids"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1248\/cpb.48.215","article-title":"Synthesis and pharmacokinetics of 1\u03b1-hydroxyvitamin D3 tritiated at 22 and 23 positions showing high specific radioactivity","volume":"48","author":"Kawase","year":"2000","journal-title":"Chem. Pharm. Bull."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s002239900546","article-title":"Sustained osteoblast nuclear receptor binding of converted 1\u03b1,25-dihydroxyvitamin D3, after admiistration of 3H-1\u03b1-hydroxyvitamin D3: A combined receptor autoradiography and radioassay time cnourse study with camparison to 3H-1\u03b1,25-dihydroxyvitamin D3","volume":"63","author":"Kioke","year":"1998","journal-title":"Calcif. Tissue Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.5059\/yukigoseikyokaishi.63.728","article-title":"Search for and development of active vitamin D3 analogues","volume":"63","author":"Kubodera","year":"2005","journal-title":"J. Syn. Org. Chem. Jpn."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1021\/jo00044a045","article-title":"An improved procedure for retro-cycloaddition of adducts from steroidal 5,7-dienes and 4-phenyl-1,2,4-triazoline-3,5-dione","volume":"57","author":"Kubodera","year":"1992","journal-title":"J. Org. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/0039-128X(92)90098-T","article-title":"Novel procedure for the preparation of 1\u03b1,3\u03b2-dihydroxy-2\u03b2-tritiated steroidal compounds","volume":"57","author":"Watanabe","year":"1992","journal-title":"Steroids"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1073\/pnas.78.8.4990","article-title":"Differentiation of mouse myeloid leukemia cells induced by 1\u03b1,25-dihydroxyvitamin D3","volume":"78","author":"Abe","year":"1981","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","first-page":"200","article-title":"Structure-function relationships in the vitamin D endocrine system","volume":"16","author":"Bouillon","year":"1995","journal-title":"Endocrine Rev."},{"key":"ref_23","unstructured":"Feldman, D., Pike, J.W., and Glorieux, F.H. (2005). Vitamin D, Elsevier Academic Press. [2nd ed.]."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3181\/00379727-178-42028","article-title":"1\u03b1-Hydroxyvitamin D2 is less toxic than 1\u03b1-hydroxyvitamin D3 in rat","volume":"178","author":"Sjoden","year":"1985","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ndt\/17.suppl_10.10","article-title":"Vitamin D analogues for secondary hyperparathyroidism","volume":"17","author":"Brown","year":"2002","journal-title":"Nephrol. Dial. Transplant"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1021\/bi00837a005","article-title":"The isolation and identification of 25-hydroxyergocalciferol","volume":"8","author":"Suda","year":"1969","journal-title":"Biochemistry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0003-9861(80)90449-X","article-title":"Isolation and identification of 24-hydroxyvitamin D2 and 24,25-dihydroxyvitamin D2","volume":"202","author":"Jones","year":"1980","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1021\/bi00677a025","article-title":"Isolation and identification of 1,25-dihydroxyvitamin D2","volume":"14","author":"Jones","year":"1975","journal-title":"Biochemistry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1021\/bi00415a058","article-title":"24,26-Dihydroxyvitamin D2: A unique physiological metabolite of vitamin D2","volume":"27","author":"Koszewski","year":"1988","journal-title":"Biochemistry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1021\/bi00573a025","article-title":"Isolation and identification of 24,25-dihydroxyvitamin D2 using the perfused rat kidney","volume":"18","author":"Jones","year":"1979","journal-title":"Biochemistry"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1021\/bi00366a051","article-title":"Isolation and identification of 1,24,25-trihydroxyvitamin D2, 1,24,25,28-tetrahydroxyvitamin D2, and 1,24,25.26-tetrahydroxyvitamin D2: New metabolites of 1,25-dihydroxyvitamin D2 produced in rat kidney","volume":"25","author":"Reddy","year":"1986","journal-title":"Biochemistry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9250","DOI":"10.1016\/S0021-9258(18)67647-1","article-title":"24-Hydroxylation of 1,25-dihydroxyergocalciferol","volume":"261","author":"Horst","year":"1986","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ki.1997.39","article-title":"Effective suppression of parathyroid hormone by 1\u03b1-hydroxyvitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism","volume":"51","author":"Tan","year":"1997","journal-title":"Kidney Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0039-128X(77)90056-3","article-title":"Synthesis of 1\u03b1-hydroxyergocalciferol","volume":"30","author":"Lm","year":"1977","journal-title":"Steroids"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1021\/ja01610a036","article-title":"A synthesis of progesterone from ergosterol","volume":"77","author":"Shepherd","year":"1955","journal-title":"J. Amer. Chem. Soc."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kubodera, N. (2009). Pharmaceutical studies on vitamin D derivatives and practical synthesis of six commercially available vitamin D derivatives that contribute to current clinical practice. Heterocycles, in press.","DOI":"10.1002\/chin.201017235"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/14\/10\/3869\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:11:16Z","timestamp":1760220676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/14\/10\/3869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,29]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2009,10]]}},"alternative-id":["14103869"],"URL":"https:\/\/doi.org\/10.3390\/molecules14103869","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,29]]}}}